Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

BREXPIPRAZOLE

BREXPIPRAZOLE

Standard Dose
0.5MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview BREXPIPRAZOLE is listed in Drugs@FDA under application 213782 (ANDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient BREXPIPRAZOLE Form and strength TABLET;ORAL - 0.5MG Sponsor ALKEM LABS LTD Submission history Latest submission status date: 2023-11-28 00:00:00.

Structured Monograph

Clinical summary

Approval overview BREXPIPRAZOLE is listed in Drugs@FDA under application 213782 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient BREXPIPRAZOLE Form and strength TABLET;ORAL - 0.5MG Sponsor ALKEM LABS LTD Submission history Latest submission status date: 2023-11-28 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.